The virosomal adjuvanted influenza vaccine

Bibliography

• Fiore AE, Shay DK, Broder K, Centers for Disease Control & Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008. MMWR 2008;57(RR07):1-60
   PubMedGoogle Scholar
• World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2000;75:281-8
   Google Scholar
• Wiselka MJ. Vaccine safety. In: Nicholson KG, Webster RG, Hay AJ, editors, Textbook of influenza. Oxford: Blackwell Science; 1998. p. 346-57
   Google Scholar
• World Health Organization. Global agenda on influenza: adopted version. Part I, Wkly Epidemiol Rec 2002;77:179-82; Part II, Wkly Epidemiol Rec 2002;77:191-6
   PubMedGoogle Scholar
• World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2002;77:230-9
   Google Scholar
• Sprenger MJW, Mulder PGH, Beyer WEP, Impact of influenza on mortality in relation to age and underlying disease, 1967–1989. Int J Epidemiol 1993;22:334-40
   PubMed Web of Science ®Google Scholar
• Barker WH, Mullooly JP. Pneumonia and influenza death during epidemics/implications for prevention. Arch Intern Med 1982;142:85-9
   PubMed Web of Science ®Google Scholar
• Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:25-44
   PubMed Web of Science ®Google Scholar
• Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005; 23:(Suppl 1):S1-9
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The unmet need in the elderly: targeting new influenza vaccines in older adults. Vaccine 2005; 23:(Suppl 1):S10-25
   PubMed Web of Science ®Google Scholar
• Remarque EJ. Influenza vaccination in elderly people. Exp Gerontol 1999;34:445-52
   Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-69
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Mellen BG, Wright PF, The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Thompson WW, Kramarz P, Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-39
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio P, Bosis S, Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006;24:629-35
   PubMed Web of Science ®Google Scholar
• Navas E, Salleras L, Dominguez A, Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3–14 years from the provider and societal perspectives. Vaccine 2007;25:3233-9
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Halloran ME, Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:1284-93
   PubMed Web of Science ®Google Scholar
• Jefferson T, Smith S, Demicheli V, Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005;365:773-80
   PubMed Web of Science ®Google Scholar
• Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003;362:1659-66
   PubMed Web of Science ®Google Scholar
• Anolik R, Spiegel W, Posner M, Influenza vaccine testing in egg sensitive patients. Ann Allergy 1992;68:69
   PubMedGoogle Scholar
• Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004;38:678-88
   PubMed Web of Science ®Google Scholar
• Hoberman A, Greenberg DP, Paradise JL, Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003;290:1608-16
   PubMed Web of Science ®Google Scholar
• IFPMA IVS International Task Force. Influenza vaccine distribution in 141 countries, 2004–2007. Third European Influenza Conference, Vilamoura, Portugal, September 14–17, 2008
   Google Scholar
• Beyer WEP, Palache AM, Baljet M, Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989;7:385-94
   PubMed Web of Science ®Google Scholar
• Provinciali M, Di Stefano G, Muzzioli M, Impaired antibody response to influenza vaccine in institutionalized elderly. Ann NY Acad Sci 1994;717:307-14
   PubMed Web of Science ®Google Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21:1769-75
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Que JU, Gluck R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 1996;14:1381-3
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;13:1557-62
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A, Safety and antigenicity of non-adjuvanted and MF59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bagarini R, Nicholson KG, Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-5
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E, Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009;106(10):3877-82
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80
   PubMed Web of Science ®Google Scholar
• de Bruijn I, Meyer I, Gerez L, Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-27
   PubMed Web of Science ®Google Scholar
• Baras B, Bouveret N, Devaster JM, A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir Viruses 2008;2(6):251-60
   PubMed Web of Science ®Google Scholar
• Belshe R, Lee M-S, Walker RE, Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004a;3:643-54
   PubMedGoogle Scholar
• Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009;8(5):607-18
   PubMed Web of Science ®Google Scholar
• Kaiser J. A one-size-fits-all flu vaccine. Science 2006;312:380-2
   PubMed Web of Science ®Google Scholar
• Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009;8(4):499-508
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal®V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002;20:B17-23
   PubMed Web of Science ®Google Scholar
• Kürsteiner O, Moser C, Lazar H, Inflexal®V–the influenza vaccine with the lowest ovalbumin content. Vaccine 2006;24:6632-5
   PubMed Web of Science ®Google Scholar
• Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin Biol Ther 2008;8(8):1177-85
   PubMed Web of Science ®Google Scholar
• Bungener L, Serre K, Bijl L, Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002;20:2287-95
   PubMed Web of Science ®Google Scholar
• Bungener L, Idema J, ter Veer W, Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res 2002;12:155-63
   PubMed Web of Science ®Google Scholar
• Arkema A, Huckriede A, Schoen P, Induction of cytotoxic T lymphocyte activity by fusion active peptide-containing virosomes. Vaccine 2000;18:1327-33
   PubMed Web of Science ®Google Scholar
• Schumacher R, Adamina M, Zurbriggen R, Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 2004;22:714-23
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener L, Stegmann T, The virosome concept for influenza vaccines. Vaccine 2005;23:S26-38
   PubMed Web of Science ®Google Scholar
• Tanzi E, Esposito S, Bojanin J, Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006;78(4):440-5
   PubMed Web of Science ®Google Scholar
• Viganò A, Zuccotti GV, Pacei M, Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-96
   PubMed Web of Science ®Google Scholar
• Setti M, Fenoglio D, Ansaldi F, Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27:3367-72
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Künzi V, Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009;27(33):4381-7
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP) Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/96, London, March 12, 1997
   Google Scholar
• Glück R, Mischler R, Finkel B, Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344:160-3
   PubMed Web of Science ®Google Scholar
• Conne P, Gauthey L, Vernet P, Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997;15:1675-9
   PubMed Web of Science ®Google Scholar
• Pregliasco F, Mensi C, Serpilli W, Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging Clin Exp Res 2001;13:38-43
   Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001;19:3472-5
   PubMed Web of Science ®Google Scholar
• Zamparo M, Conversano M, Mastronuzzi L, Comparison of the safety and immunogenicity of two adjuvanted influenza vaccines in elderly subjects. 1st International Conference on Influenza Vaccines for the World (IVW), Lisbon, Portugal, May 24-26, 2004: poster no. 1
   Google Scholar
• Gaeta G, Storaiuolo G, Precone D, Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine 2002;20:B33-5
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Pariani E, Amendola A, Influenza vaccination in patients with cirrhosis and liver transplant recipients. Vaccine 2009;27:3373-5
   PubMed Web of Science ®Google Scholar
• Herzog C, Metcalfe IC, Schaad UB. Virosome influenza vaccine in children. Vaccine 2002;20:B24-8
   PubMed Web of Science ®Google Scholar
• Schaad UB, Bühlmann R, Burger R, Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000;44:1163-7
   PubMed Web of Science ®Google Scholar
• Kanra G, Marchisio P, Feiterna-Sperling C, Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-6. Erratum in: Pediatr Infect Dis J. 2004 23(6):503
   PubMed Web of Science ®Google Scholar
• Salleras L, Dominguez A, Pumarola T, Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: a prospective cohort study. Vaccine 2006;24:6638-42
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio M, Bosis S, Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006;24:629-35
   PubMed Web of Science ®Google Scholar
• Marchisio P, Esposito S, Bianchini S, Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis Media. Pediatr Infect Dis J 2009;28:855-9
   PubMed Web of Science ®Google Scholar
• Esposito S, Tagliabue C, Pelucchi C, Efficacy of the influenza vaccination in asthmatic children. ICAAC, Chicago, 17-20 September 2007 Poster G-1711
   Google Scholar
• Zuccotti GV, Cucchi C, Sala D, Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr 2002;91:486-7
   PubMed Web of Science ®Google Scholar
• Amendola A, Boschini A, Colzani D, Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001;65:644-8
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Amendola A, Viganò A, Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 2007;25:6692-8
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Scaramuzza A, Riboni S, Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009;27(39):5357-62
   PubMed Web of Science ®Google Scholar
• Ciriminna S. Prevention of acute respiratory tract infections by an adjuvanted virosomal influenza vaccine and its tolerability: outcome of the 1999-2000 vaccination program in Sicily. J Prev Med Hyg 2002;43:52-5
   Google Scholar
• Künzi V, Dornseiff M, Horwath J, Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 2009;27:1261-5
   PubMed Web of Science ®Google Scholar
• Esposito S, Gasparini C, Martelli A, Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008;26:4664-8
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Influenza. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors, Red book: 2006 Report of the Committee on InfectiousDiseases. 27th edition. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 401-11
   Google Scholar
• Ryan J, Zoellner Y, Gradl B, Establishing the health and economic impact of influenza vaccination within the European Union 25 Countries. Vaccine 2006;24:6812-22
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G, Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E, Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-40
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003;21:1268-74
   PubMed Web of Science ®Google Scholar
• Ruf BR, Colberg K, Frick M, Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004;32:191-8
   PubMed Web of Science ®Google Scholar
• Murasko DM, Bernstein ED, Gardner EM, Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002;37:427-39
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD, T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:6333-9
   PubMed Web of Science ®Google Scholar